Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 2;38(5):BSR20180677.
doi: 10.1042/BSR20180677. Print 2018 Oct 31.

TUG1 promotes prostate cancer progression by acting as a ceRNA of miR-26a

Bin Yang  1 , Xiaodi Tang  2 , Zhixin Wang  3 , Daju Sun  4 , Xin Wei  5 , Youpeng Ding  5
Affiliations

TUG1 promotes prostate cancer progression by acting as a ceRNA of miR-26a

Bin Yang et al. Biosci Rep. .

Abstract

Previous studies have demonstrated that taurine-upregulated gene 1 (TUG1) was aberrantly expressed and involved in multiple types of cancer; however, the expression profile and potential role of TUG1 in prostate cancer (PCa) remains unclear. The aim of the present study was to evaluate the expression and function of TUG1 in PCa. In the present study, we analyzed TUG1 expression levels of PCa patients in tumor and adjacent normal tissue by real-time quantitative PCR. Knockdown of TUG1 by RNAi was performed to explore its roles in cell proliferation, migration, and invasion. Here we report, for the first time, that TUG1 promotes tumor cell migration, invasion, and proliferation in PCa by working in key aspects of biological behaviors. TUG1 could negatively regulate the expression of miR-26a in PCa cells. The bioinformatics prediction revealed putative miR-26a-binding sites within TUG1 transcripts. In conclusion, our study suggests that long non-coding RNA (lncRNA) TUG1 acts as a functional oncogene in PCa development.

Keywords: EMT; LncRNA; PCa; TUG1; metastasis; miR-26a.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no competing interests associated with the manuscript.

Figures

Figure 1
Figure 1. Expression of TUG1 and miR-26a in PCa tissue samples
(A) qRT-PCR showing expression level of TUG1 in PCa tissues and adjacent non-cancerous tissues; (B) qRT-PCR showing expression level of miR-26a in PCa tissues and adjacent non-cancerous tissues; (C) miR-26a expression was negatively associated with TUG1 expression in PCa tissues; (D) qRT-PCR showing expression level of TUG1 in PCa cell lines. All tests were performed at least three times. Data were expressed as mean ± S.D.; **P<0.01.
Figure 2
Figure 2. siRNA was employed to knockdown TUG1 and influence of TUG1 on cellular proliferation
(A,B) We employed siRNA to enhance efficiency of TUG1 knockdown in PCa cell lines; (C) CCK8 assay showing knockdown of TUG1 inhibited cell proliferation of DU145 cells; (D) CCK8 assay showing knockdown of TUG1 inhibited cell proliferation of PC3 cells. All tests were performed at least three times. Data were expressed as mean ± S.D.; *P<0.05, **P<0.01.
Figure 3
Figure 3. Influence of TUG1 on cell apoptosis and cell cycle
(A) Flow cytometry showed that DU145 cells transfected with TUG1 siRNA had higher apoptotic rate in comparison with control cells; (B) flow cytometry showed that PC3 cells transfected with TUG1 siRNA had higher apoptotic rate in comparison with control cells; (C) DU145 cells transfected with si-TUG1 had cell-cycle arrest at the G1-G0 phase; (D) PC3 cells transfected with si-TUG1 had cell-cycle arrest at the G1-G0 phase; all tests were performed at least three times. Data were expressed as mean ± S.D.; **P<0.01.
Figure 4
Figure 4. TUG1 regulates cell migration and invasion of PCa
(A) Inhibition of invasion of DU145 cells by TUG1 siRNA; (B) inhibition of invasion of PC3 cells by TUG1 siRNA; (C) knockdown of TUG1 reverses EMT in DU145 cells; (D) knockdown of TUG1 reverses EMT in PC3 cells. All tests were performed at least three times.
Figure 5
Figure 5. TUG1 inhibited miR-26a expression in PCa cells
(A) The wild-type or mutant miR-26a-binding sites in TUG1 were inserted into pMIR-report luciferase vector. Luciferase activity was detected in PCa cells co-transfected with miR-26a or negative control (miR-control) and reporter plasmids containing WT-TUG1 (wild type) or MUT-TUG1 (mutant type). The normalized luciferase activity in the miR-control group was used as the relative luciferase activity. (B) Expression levels of miR-26a in different PCa cell lines were determined by qRT-PCR. (C) The co-transfection of miR-26A and TUG1 by pcDNA3.1. The expression of miR-26a was detected by qRT-PCR. All tests were performed at least three times. Data were expressed as mean ± S.D.; **P<0.01.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Srigley J.R., Amin M., Boccon-Gibod L., Egevad L., Epstein J.I., Humphrey P.A. et al. (2005) Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives. Scand. J. Urol. Nephrol. Suppl. 216, 8–19 10.1080/03008880510030914 - DOI - PubMed
    1. Stephenson A.J., Kattan M.W., Eastham J.A., Dotan Z.A., Bianco F.J. Jr, Lilja H. et al. (2006) Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J. Clin. Oncol. 24, 3973–3978 10.1200/JCO.2005.04.0756 - DOI - PubMed
    1. Barlow L.J., Badalato G.M., Bashir T., Benson M.C. and McKiernan J.M. (2010) The relationship between age at time of surgery and risk of biochemical failure after radical prostatectomy. BJU Int. 105, 1646–1649 10.1111/j.1464-410X.2009.08977.x - DOI - PubMed
    1. Gibb E.A., Brown C.J. and Lam W.L. (2011) The functional role of long non-coding RNA in human carcinomas. Mol. Cancer 10, 38 10.1186/1476-4598-10-38 - DOI - PMC - PubMed
    1. Xu M.D., Qi P. and Du X. (2014) Long non-coding RNAs in colorectal cancer: implications for pathogenesis and clinical application. Mod. Pathol. 27, 1310–1320 10.1038/modpathol.2014.33 - DOI - PubMed